Skip to content

News

Ovarian Cancer Research Fund Commemorates Ovarian Cancer Aw...

Ovarian Cancer Research Fund Commemorates Ovarian Cancer Awareness Month with over $6 Million in Grants and New Initiatives

The largest private funder of ovarian cancer research awarded $6.3 million in grants while also launching new events and partnerships (September 11, 2015) –Ovarian Cancer Research Fund (OCRF), has awarded $6.3 million in grants to scientists working to cure ovarian cancer, as well as to hospitals supporting patients through OCRF’s signature Woman to Woman program. … Continued

Teaming Up Against Ovarian Cancer

Teaming Up Against Ovarian Cancer

Check out this guest post by Alan D. D’Andrea, MD, and Elizabeth M. Swisher, MD from the  SU2C-OCRF-OCNA-NOCC Dream Team that originally appeared on Cancer Research Catalyst, the official blog of the American Association for Cancer Research, the Scientific Partner of Stand Up 2 Cancer. September is Ovarian Cancer Awareness Month, when we scientists and advocates renew our determination to find new solutions to this devastating disease. This year we are pleased to have seen some encouraging signs. At the Annual Meeting of the American Association for Cancer Research (AACR) in April, scientists reported that a combination of two drugs, olaparib and BKM120, showed clinical benefit for women with high-grade serous ovarian cancer (as well as women with triple-negative breast cancer). Click plus sign to read on.

OCRF Research Shows Heart Medication Prolongs Life in Ovari...

OCRF Research Shows Heart Medication Prolongs Life in Ovarian Cancer Patients

(August 26, 2015) Women with epithelial ovarian cancer who happened to be taking nonselective beta-blockers for hypertension survived longer than those who were not taking the drugs, according to a large multicenter retrospective study.  The study was funded in part by an OCRF grant to Dr. Anil Sood at MD Anderson Cancer Center. Survival was … Continued

Multi-gene Testing for Ovarian Cancer Risk is Clinically Us...

Multi-gene Testing for Ovarian Cancer Risk is Clinically Useful

(August 21, 2015) A study published online in JAMA Oncology this month shows that screening women with a suspected risk of hereditary breast or ovarian cancer with a multigene panel (which looks for mutations in many genes), identifies more people with cancer risk related gene mutations than screening for BRCA1 and 2 alone. Importantly, identifying … Continued

RAD51 Mutations Confer Moderate Risk of Ovarian Cancer

RAD51 Mutations Confer Moderate Risk of Ovarian Cancer

(August 19, 2015)  Deleterious mutations in RAD51C and RAD51D genes are associated with increased risk of epithelial ovarian cancer (EOC), according to a study published online Aug. 10 in the Journal of Clinical Oncology. Honglin Song, PhD, from the University of Cambridge in the United Kingdom, and colleagues conducted a genetic study using germline DNA … Continued

OCRF Research Finds Combination Immunotherapy Promising

OCRF Research Finds Combination Immunotherapy Promising

(August 19, 2015) Whereas chemotherapy kills cancer cells only while it is being administered, immunotherapy can lead to an adaptive immune response that persists long after treatment is ceased. By simple analogy, whereas aspirin provides temporary pain relief, a polio vaccine provides lifelong protection. Unfortunately, just as tumors develop resistance to conventional therapies, tumors also … Continued

Ovarian Cancer Survival Rates Higher Than Thought

Ovarian Cancer Survival Rates Higher Than Thought

(August 17, 2015) A study from the University of California, Davis found that one-third of women with ovarian cancer survive at least 10 years after diagnosis. The study, published in the Journal of Obstetrics and Gynecology, linked high survival rates with younger ages, early stages, and tumor type but they also found many exceptions to … Continued

Study Finds Intraperitoneal Chemotherapy Underutilized

Study Finds Intraperitoneal Chemotherapy Underutilized

(August 4, 2015) A study published online in the Journal of Clinical Oncology reports that although the use of intraperitoneal chemotherapy (IP)/IV chemotherapy increased significantly at major cancer centers between 2003 and 2012, fewer than 50% of eligible patients received it. Previous studies have shown that the use of IP chemotherapy significantly improves survival among … Continued

OCRF Research Finds Gene Therapy May Help Patients with Rec...

OCRF Research Finds Gene Therapy May Help Patients with Recurrent Ovarian Cancer

(July 30, 2015) Recurrent ovarian cancer patients have more hope today, thanks to OCRF-funded research by David Pepin, PhD at Massachusetts General Hospital. Dr. Pepin and his colleagues found that gene therapy that delivers a protein that suppresses the development of female reproductive organs may improve survival rates in patients with ovarian cancer that has … Continued

Younger Women with Low Grade Ovarian Cancer Face Worse Outc...

Younger Women with Low Grade Ovarian Cancer Face Worse Outcomes

(July 29, 2015) Research published online in the Journal of Clinical Oncology shows that upon completion of primary therapy, women with low-grade serous carcinoma of the ovary (LGSOC) or peritoneum (LGSPC) who are under the age of 35 and have persistent disease face worse outcomes. Researchers at the University of Texas MD Anderson Cancer Center … Continued

OCRF Research Shows PARP/Immune Therapy Combo Shows Promise

OCRF Research Shows PARP/Immune Therapy Combo Shows Promise

(July 23, 2015) New OCRF-funded research demonstrates that combining a PARP-inhibitor with immune therapy results in tumor rejection and long-term survival in a mouse model of BRCA1-deficient ovarian cancer.  The study, published in Cancer Immunology Research, was funded by an OCRF Liz Tilberis Early Career Award to Sarah Adams, MD. The benefit of this combination … Continued

Comparison of Clear Cell and Serous Ovarian Cancer- Charact...

Comparison of Clear Cell and Serous Ovarian Cancer- Characteristics and Prognosis

(July 21, 2015) A group of Chinese researchers compared clinical characteristics and prognosis between ovarian clear cell carcinoma (CCC) and serous carcinoma (SC), and found that women with ovarian CCC presented at a younger age and early stage. Patients with ovarian CCC also had a longer time to recurrance, but they had similar overall survival … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.